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ABSTRACT
Objectives: To review studies developing or validating
a prognostic model for individual venous
thromboembolism (VTE) recurrence risk following
cessation of therapy for a first unprovoked VTE.
Prediction of recurrence risk is crucial to informing
patient prognosis and treatment decisions. The review
aims to determine whether reliable prognostic models
exist and, if not, what further research is needed within
the field.
Design: Bibliographic databases (including MEDLINE,
EMBASE and the Cochrane Library) were searched
using index terms relating to the clinical field and
prognosis. Screening of titles, abstracts and
subsequently full texts was conducted by 2 reviewers
independently using predefined criteria. Quality
assessment and critical appraisal of included full texts
was based on an early version of the PROBAST
(Prediction study Risk Of Bias Assessment Tool) for risk
of bias and applicability in prognostic model studies.
Setting: Studies in any setting were included.
Primary and secondary outcome measures: The
primary outcome for the review was the predictive
accuracy of identified prognostic models in relation to
VTE recurrence risk.
Results: 3 unique prognostic models were identified
including the HERDOO2 score, Vienna prediction model
and DASH score. Quality assessment highlighted the
Vienna, and DASH models were developed with
generally strong methodology, but the HERDOO2 model
had many methodological concerns. Further, all models
were considered at least at moderate risk of bias,
primarily due to the need for further external validation
before use in practice.
Conclusions: Although the Vienna model shows the
most promise (based on strong development
methodology, applicability and having some external
validation), none of the models can be considered ready
for use until further, external and robust validation is
performed in new data. Any new models should
consider the inclusion of predictors found to be
consistently important in existing models (sex, site of
index event, D-dimer), and take heed of several
methodological issues identified through this review.
PROSPERO registration number:
CRD42013003494.
INTRODUCTION
Venous thromboembolism (VTE) is the third
most common cardiovascular disease after
heart attack and stroke; it is a chronic condi-
tion with estimated incidence at 1 per 1000
person years.1–3 VTE often presents as deep
vein thrombosis (DVT), with some patients
suffering an embolism in the lungs known as
a pulmonary embolism. An initial VTE devel-
oped in the presence of a known provoking
factor may be termed ‘provoked’, while those
developed in the absence of clinical risk
factors may be termed ‘unprovoked’.3 4
There are several known predisposing risk
factors including surgery, trauma, hormone
intake, pregnancy and prolonged immobil-
ity.3 5 Such factors can be considered as
acquired risk factors, because they are transi-
ent, that is, while they increase the risk of an
initial VTE, they are temporary, and when
the provoking factor is removed, the patient
is at a low risk of recurrence, for example,
postsurgery.3–5
Strengths and limitations of this study
▪ To our knowledge, this is the first systematic
review identifying prognostic models for venous
thromboembolism recurrence risk in the unpro-
voked population, using a robust systematic
methodology.
▪ The study is also the first to assess the validity
of the existing models in terms of risk of bias
and applicability.
▪ We were unable to perform a quantitative ana-
lysis of the identified articles due to a lack of
homogeneity in many areas, including the pre-
dictors used, model types and study
populations.
▪ All models require further independent external
validation, and as such the true performance of
the models in the wider unprovoked population
must be assessed in new research.
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The aim of therapy for VTE is twofold, initially to
prevent extension of the acute thrombosis, and second-
arily to prevent both recurrence and long-term sequelae
such as post-thrombotic syndrome and pulmonary
hypertension. Current treatment comprises initial man-
agement with heparin, usually low molecular weight
heparin for a minimum of 5 days, overlapping with oral
anticoagulant (OAC) therapy (usually warfarin in the
UK) until the international normalised ratio is above
two. It is usual to treat an initial VTE for a minimum of
3 months; however, the optimum duration of therapy
beyond this is unclear.6 7 Treatment with novel oral
anticoagulants is a new alternative treatment to heparin
and warfarin.
Owing to the transient nature of provoking factors,
patients with a ﬁrst unprovoked VTE are at much higher
risk of recurrent VTE (approaching 30% at 5 years after
cessation of therapy) as the cause is unknown.3 5
Prevention of recurrent VTE poses a difﬁcult clinical
decision problem; a balance must be struck between the
risks of recurrent thrombosis if anticoagulant treatment
is stopped versus the risks of bleeding associated with
continued anticoagulation therapy.3 6
Therefore, it is important to identify individuals with a
high risk of VTE recurrence compared with the risk of
major bleeding on anticoagulation, in order to inform
treatment strategies. However, the population of patients
with unprovoked VTE is highly heterogeneous and risk
of VTE recurrence varies considerably across indivi-
duals.8–10 Therefore, there is much interest in develop-
ing prognostic models for VTE recurrence. A prognostic
model is a statistical equation that predicts an indivi-
dual’s outcome risk based on the combination of their
values of multiple predictors (eg, age, sex, biomar-
kers).11 A key stage of prediction model research is
model development. This uses a data set to identify
important predictors and then develops the model equa-
tion; it usually also examines the model’s apparent per-
formance in this same data, possibly using resampling
techniques to adjust for optimism (internal validation).
The next stage is external validation, which uses data
external to the model development data and its source,
and examines whether the model predictions are accur-
ate in another (related) setting. External validation is
crucial as model performance is usually overoptimistic
when considered only in the development data set.11–13
Validation typically focuses on discrimination perform-
ance (ie, the model’s ability to separate those with and
without the outcome) and calibration performance (ie,
the agreement between the model’s predicted risk and
the observed outcome risk).
Aims of the review
A reliable prognostic model is needed for the unpro-
voked VTE population, in order to inform clinical and
patient decision-making with regard to treatment strat-
egies,14 in particular whether or not to extend treatment
beyond the initial period (eg, 3 months) with OACs to
prevent recurrent VTE.
The aim of this systematic review was to identify and
summarise studies developing or validating a prognostic
model for individual VTE recurrence risk following ces-
sation of therapy for a ﬁrst unprovoked VTE. Through
the identiﬁcation of existing studies, the review will help
to determine whether reliable prognostic models exist
and, if not, what further research is needed within the
ﬁeld. In particular, the review appraises the evidence for
and against each existing model, to help clinicians and
other practitioners to better understand their strengths
and weaknesses,14 allowing more informed decisions to
be made on which (if any) models to use in practice. A
protocol for the review was registered with PROSPERO
(CRD42013003494) and published in Systematic
Reviews.15
METHODS
Search strategy
The following bibliographic databases were searched:
Cochrane Library (Wiley; including the Cochrane
Database of Systematic Reviews, DARE, HTA Databases
and CENTRAL Register of Controlled Trials), MEDLINE
(Ovid) 1950 to July 2014, MEDLINE In—Process &
Other Non-Indexed Citations (Ovid) to date and
EMBASE (Ovid) 1980 to July 2014. Searches used index
terms and text words that encompassed the patient
group supplemented by terms relating to recurrence or
adverse outcome and prognostic factors (see sample
MEDLINE search in online supplementary appendix 1).
Publicly available trial registers were also searched,
such as ClinicalTrials.gov, UK Clinical Research Network
Study Portfolio Database (UKCRN), WHO International
Clinical Trials Registry Platform and the metaRegister of
Controlled Trials (mRCT). Reference lists of all included
papers were checked and subject experts were con-
tacted. No restrictions on publication language were
applied.
In addition, abstracts from the Conference
Proceedings Citation Index (CPCI) were searched in
order to capture studies that were not yet fully published.
Selection/inclusion criteria
Study design
Studies of any design (eg, cohorts, randomised con-
trolled trials) or systematic reviews that developed, com-
pared or validated a prognostic model (or clinical
prediction rule based on a model) utilising multiple (at
least two) predictors to predict the risk of recurrent VTE
or adverse outcome (mortality or bleeding) following
cessation of therapy for a ﬁrst unprovoked VTE.
Patient group
Patients aged ≥18 years with a ﬁrst unprovoked VTE
where the patient has received at least 3 months treat-
ment with an OAC therapy. Studies with mixed
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populations (including those outside of remit) were
included provided that appropriate data for the deﬁned
group of patients was extractable.
Setting
Studies in any setting were included.
Potential prognostic models
Studies must have reported a prognostic model utilising
multiple predictors to predict the risk of recurrent VTE
or adverse outcome following cessation of therapy for a
ﬁrst unprovoked VTE. A prognostic model was deﬁned
as a combination of at least two predictors within a statis-
tical model, used to predict an individual’s risk of
outcome (eg, VTE recurrence).
Study selection
Study selection followed a two-step process. Titles (and
abstracts where available) were initially screened by two
reviewers independently, using predeﬁned screening cri-
teria. These were broadly based on whether studies, (1)
included patients with a ﬁrst unprovoked VTE, who
received a minimum of 3 months OAC therapy and (2)
developed or examined prognostic models in relation to
individual prediction of VTE recurrence or other
adverse outcomes (mortality or bleeding).
Full texts of any potentially relevant articles were then
obtained and two reviewers independently applied the
full inclusion criteria (see online supplementary appen-
dix 2). Any discrepancies between reviewers were
resolved by discussion or by referral to a third reviewer.
Portions of non-English language studies were translated
where necessary to facilitate study selection and subse-
quent data extraction. The study selection process was
documented using the PRISMA ﬂow diagram. Any rele-
vant systematic reviews identiﬁed were screened for
further primary studies. Reference management software
(Endnote) was used to record reviewer decisions, includ-
ing reasons for exclusion.
Data extraction
In those articles deemed relevant, data extraction was
then conducted independently by two reviewers using
an in-depth piloted data extraction form. Disagreements
were resolved through discussion or referral to a third
reviewer.
Data extraction included the following elements:
▸ Study characteristics (eg, sample size, country, year);
▸ Study design characteristics (eg, design, length of
follow-up);
▸ Patient characteristics (eg, summaries of age, sex,
family history, treatment details in the sample);
▸ Candidate predictors considered (eg, any thresholds
used for continuous predictors, methods of measure-
ment, timing of measurement postcessation of
therapy);
▸ Outcome measures (eg, recurrence of VTE, mortality,
bleeding);
▸ Statistical methods employed and how predictors
included in the analysis were handled (eg, continu-
ous vs dichotomised);
▸ Prognostic model details, including the ﬁnal model
equation and included predictors; how the model was
developed and how it can be used to obtain an indivi-
dual’s risk probability; and any internal and external
validation performance statistics for model perform-
ance (including discrimination and calibration)
together with their CIs.
Assessment of study quality
The quality (risk of bias) of any studies developing or
evaluating a prognostic model was assessed by piloting a
version of PROBAST (Prediction study Risk Of Bias
Assessment Tool), a tool for assessing risk of bias and
applicability of prognostic model studies, that was
nearing completion and ready for piloting when this
review was undertaken (Wolff R, Whiting P, Mallett S,
et al, personal communication).
Particular elements were considered in the following
domains:
▸ Patient selection, such as
– What study design was used (eg, prospective),
– If appropriate inclusions and exclusions were used,
– Whether patients had similar disease presentation,
or if this was accounted for in analyses.
▸ Outcomes, such as whether
– The outcome deﬁnition was prespeciﬁed,
– Included predictors were excluded from the
outcome deﬁnition,
– The same deﬁnition and assessment was used for
predictors and outcomes in all patients,
– The outcome was determined blind to predictor
information.
▸ Predictors, such as whether
– The same predictor deﬁnitions were used for all
patients,
– Predictors were measured blinded to outcome data,
– All predictor information was available at the time
the model was intended for use,
– Non-linear associations for continuous predictors
were considered and, if undertaken, predictor cat-
egorisation was not data driven.
▸ Sample size, such as
– Whether there was a prespeciﬁed sample size con-
sideration for model development accounting for
numbers of events and multiple comparisons in
selection of predictors,
– Whether all enrolled patients were included in
analyses,
– How much data were available for external
validation.
▸ Missing data, including whether
– There was adequate reporting on completeness of
data,
– Multiple imputation was considered.
Ensor J, et al. BMJ Open 2016;6:e011190. doi:10.1136/bmjopen-2016-011190 3
Open Access
group.bmj.com on November 24, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
▸ Statistical analysis, such as
– Handling of continuous predictors,
– Selection of possible predictors irrespective of uni-
variable analyses,
– Whether weights assigned to predictors in the ﬁnal
model’s statistical equation related to the same
regression coefﬁcients as from the ﬁtted model in
the development data.
▸ Internal and external model validation
– Whether model validations are reported and how
these were obtained, in particular whether overﬁt-
ting and optimism was accounted for using boot-
strapping or shrinkage (during internal validation).
Summarising identified evidence
For each unique model identiﬁed, we summarised narra-
tively the evidence available using the data extracted. In
particular, we summarised the model development and
validation methodology, the included predictors and
how they were coded, the speciﬁcation of the model and
how it can be used, whether the model was validated
internally and externally (and if so how), and the
reported performance of the model in terms of calibra-
tion and discrimination. The PROBAST evaluation was
used to determine the risk of bias of the model (ie,
whether the model is likely to work as intended for the
VTE population of interest), with models classed as low,
moderate or high risk of bias.
The consistency of development methods used and
main ﬁndings were examined to identify whether studies
at higher risk of bias produced different results and con-
clusions to those considered to be at low risk of bias.
If multiple studies were found that validated the same
prognostic model, it was planned to synthesise calibra-
tion (eg, expected/observed events) and discriminatory
statistics (eg, C-statistic) using a random-effects
meta-analysis,16 17 to summarise the model’s average per-
formance across different settings and its potential per-
formance in a future setting.
Relevant articles identified outside of search dates
Two relevant studies were identiﬁed since the literature
searches were performed; these were published in
February 201518 and September 2015, respectively.19
The ﬁrst study is an external validation of the Vienna
prediction model using individual participant data
(IPD) from ﬁve studies, and the later study is an external
validation of the updated Vienna prediction model in a
prospective multicentre cohort study; both of these will
be discussed in detail later as evidence found outside
the systematic review searches.18–20
RESULTS
Quantity of research available
Searching of bibliographic databases resulted in 13 516
records identiﬁed after automatic removal of 1879 dupli-
cates. A further 2747 duplicate records were manually
removed, leaving 10 769 records to be screened for
inclusion. Screening of titles and abstracts identiﬁed
10 485 records irrelevant to the review question. Full-text
articles were sought for eligibility assessment, three arti-
cles were unobtainable from the British library21–23 and
a further three articles were unable to be translated into
English24–26 out of 19 non-English language articles (ie,
16 translated). Of the 278 full-text articles assessed for
inclusion, 258 articles were excluded with:
▸ Ninety-one articles excluded as discussion or review
articles that did not develop or update a prognostic
model;
▸ One hundred and ﬁfty articles were excluded based
on issues related to the model (eg, not for individual
prediction, emphasis on the effect of a single pre-
dictor, etc);
▸ Three articles were excluded based on the study
population;
▸ Fourteen were excluded based on population and
model issues (see ﬁgure 1).
Twenty articles, therefore, met the inclusion criteria
after screening, comprising seven ongoing studies,27–33
eight conference abstracts,34–41 one project record refer-
ring to the project this work forms part of42 43 and four
full-text peer-reviewed articles.8–10 44
The authors of the 15 conference abstracts and
ongoing studies were contacted to seek additional infor-
mation. Based on author responses, 13 of the 15
abstracts/ongoing studies were associated with the four
full-text articles included. The authors of the remaining
two articles (which were both abstracts) did not respond
to further enquiry, and so no further publications could
be found to supplement the available abstracts.27 35
The ﬁrst abstract related to a study by Raskob et al,35
based on data from the EINSTEIN extension study,45
and aimed to identify a subgroup of patients at high and
low risk of recurrent VTE. Further information regard-
ing the study was unavailable from the included abstract;
therefore, it was unclear whether a prognostic model
was developed and if individual recurrence risk could be
predicted from such a model. The second abstract
relates to the ongoing VISTA study,27 discussed later in
the article.
We concentrate now on summarising and critiquing in
detail the full-text articles included in the review (and
their 13 associated abstracts). First, a brief introduction to
the full-text articles and the models developed is given.
HERDOO2
Rodger et al9 used conditional logistic regression to
develop a prognostic model for use as a clinical decision
rule. This suggested that a female patient with less than
two predictors (post-thrombotic signs, D-dimer level
≥250 µg/L, body mass index (BMI)≥30 kg/m2 or
age≥65 years) could potentially safely discontinue OAC
therapy after 5–7 months of initial OAC therapy for an
unprovoked VTE. A low risk (<3% annual recurrence
risk) group of males could not be identiﬁed in the study,
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and therefore Rodger et al9 recommended that all male
patients continue OAC therapy.
Vienna prediction model
Eichinger et al8 44 used a Cox proportional hazards
model to develop a prognostic model including sex, site
of index event and D-dimer as predictors. A nomogram
based on the prognostic model was derived to allow easy
implementation of the model and can be used to calcu-
late patient’s cumulative recurrence rate at 12 and
60 months from cessation of therapy, with estimated
95% CIs.8 Another full-text article included in the
review describes an update to the proposed Vienna
model (discussed later), by recalculating the model at 3,
9 and 15 months after cessation of therapy using new
measurements of D-dimer levels at these time points.
Eichinger et al44 used a dynamic prediction approach in
the updated model and adapted a Fine-Gray model to
allow for the competing risk between recurrence and
death (in some of those who restart therapy).
DASH score
Tosetto et al10 used a Cox proportional hazards model to
develop a prognostic model including predictors for
abnormal D-dimer levels (+2 score), age≤50 years
(+1 score), male sex (+1 score) and hormone use
(−2 score). This proposed score can be used to calculate
patient’s cumulative recurrence risk at 1, 2 and 5 years
Figure 1 PRISMA flow diagram
showing the quantity of research
available.
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Table 1 Summary of patient characteristics in included model studies
Model HERDOO2 Vienna DASH
Measurement statistics used Mean (SD) or frequency (%)
Median (25th, 75th centiles)
or frequency (%) Median or per cent
Patient characteristic n Recurrence n No recurrence n All n Recurrence n No recurrence
Age (years) 91 53.6 (14.8) 555 52.3 (17.9) 929 54 (43, 63) 239 63 1579 61
Male proportion 91 63 (69.2) 555 269 (48.5) 929 562 (60) 239 69.40% 1579 48.60%
Site (distal DVT) proportion 91 NA 555 NA 929 164 (17.7) 239 NA 1579 NA
Site (proximal DVT) proportion 91 NA 555 NA 929 327 (35.2) 239 NA 1579 NA
Site (PE) proportion 91 NA 555 NA 929 438 (47.1) 239 NA 1579 NA
BMI (kg/m2) 91 30.3 (7.6) 555 28.9 (7.1) 909 27.1 (24.4, 30.1) * 27.2 * 27.2
D-dimer (µg/L)† 91 383 (738) 555 294 (314) 832 355 (236, 558) 239 67.7%‡ 1579 42%‡
Factor V Leiden proportion 91 19 (20.9) 554 81 (14.6) 916 224 (24.4) 239 NA 1579 NA
Duration of OAC (months) 91 5 to 7 555 5 to 7 929 6.6 (6.1, 8.0) 239 6.7 1579 6.8
Duration of follow-up (months) 18 (1, 47)§ 43.3 (14.7, 78.5) 22.4
*BMI data available for 802 participants, no reporting of number of participants by event status.
†D-dimer measured in ng/mL within the DASH article.
‡DASH reported the percentage with abnormal D-dimer, defined as ≥500 ng/mL.
§Follow-up for HERDOO2 presented as mean (range).
NA—the information was not provided for these fields. In particular, both the HERDOO2 and DASH studies did not include patients with distal DVT index events a priori. And the DASH study
did not provide figures for the proportion of patients with factor V Leiden, but the percentages of patients with thrombophilia were 23.4% and 20.9% for recurrence and non-recurrence,
respectively.
BMI, body mass index; DVT, deep vein thrombosis; OAC, oral anticoagulants; PE, pulmonary embolism.
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from cessation of therapy, with estimated 95% CIs.
Tosetto et al10 suggest that a combined DASH score ≤1
would indicate an annual recurrence risk <5% and
therefore indicate that a patient could potentially stop
OAC therapy, conversely a DASH score >1 would indi-
cate annual recurrence risk >5% and thus suggest
patients should potentially continue OAC therapy.
The population characteristics of the three study
populations were broadly similar across predictors mea-
sured in all studies (see table 1). The median age of
patients in the DASH population was somewhat higher
than that of the HERDOO2 and Vienna study popula-
tions, and the Vienna study included extended
follow-up compared with the other studies, both of
which could affect estimates of predictor effects in the
models. Throughout this review, these articles will be
referred to using the name of the corresponding
model developed, as given above (ie, HERDOO2,
Vienna and DASH).
QUALITY ASSESSMENT AND CRITICAL APPRAISAL
Patient selection and outcomes
All of the three articles developed models based on data
collected using a prospective design (see table 2), which
is ideal for prognostic modelling as predictor informa-
tion can be collected blind to patient outcome. Across
all three articles, recurrent VTE (at various predicted
time points) was the primary outcome (see table 2), and
was objectively conﬁrmed and independently adjudi-
cated. Detection bias was limited in all three articles by
prespeciﬁcation of outcome deﬁnitions, with the same
deﬁnition and assessment used for all patients (within
each study), meaning systematic differences in the deter-
mination of outcomes were avoided.
The inclusion/exclusion criteria used in the three arti-
cles is summarised in table 3, and common criteria
included the exclusion of patients with high-risk throm-
bophiliac conditions, patients <18 years old and patients
treated with <3 months OAC therapy.
Table 2 Study characteristics
Model HERDOO2 Vienna DASH
Year of publication 2008 2010 2012
Country Four countries (unspecified) Austria Austria, Canada, Italy,
Switzerland, UK, USA
Study setting 12 tertiary care centres, patients
enrolled between October 2001
and March 2006
Recruited from 4 thrombosis
centres in Vienna between July
1992 and August 2008
Patient-level meta-analysis of
previously published studies
(11)
Study design Prospective cohort study Prospective cohort study Individual patient data from 7
prospective studies
Clinical outcome Recurrent VTE Recurrent VTE Recurrent VTE
Key prediction
time points
(months)
12 months 12, 60 months 12, 24, 60 months
Total sample size 646 929 1818
Events 91 176 239
VTE, venous thromboembolism.
Table 3 Study inclusion/exclusion criteria
Model HERDOO2 Vienna DASH
Inclusion
criteria
First unprovoked VTE
Received OAC 5–7 months
No recurrent VTE on treatment
First unprovoked VTE
Age≥18
Received OAC≥3 months
First unprovoked VTE
Including thrombophilic
blood abnormalities where there were no
other VTE risks
Exclusion
criteria
Age<18
Deficiency in antithrombin,
protein C or S
Presence of lupus
anticoagulant
Already discontinued OAC
Geographically inaccessible to
follow-up
Not proximal DVT or PE index
event
Deficiency in antithrombin,
protein C or S
Presence of lupus
anticoagulant
Presence of cancer
Known antiphospholipid antibodies
Antithrombin deficiency
Not proximal DVT or PE index event
DVT, deep vein thrombosis; OAC, oral anticoagulants; PE, pulmonary embolism; VTE, venous thromboembolism.
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All articles only included patients with a ﬁrst unpro-
voked VTE, but deﬁnitions of unprovoked varied some-
what (see table 4). The HERDOO2 and DASH models
both included patients with hormone intake at time of
index event, while the HERDOO2 model also included
pregnancy-associated VTE at index event within its deﬁn-
ition of unprovoked VTE. The DASH model study justi-
ﬁes including hormone intake as unprovoked because
some evidence suggests hormone therapy is a weak pre-
dictor for VTE recurrence.10 46 However, evidence sug-
gests that these risk factors are acquired,3 4 and
inclusion of patients outside the unprovoked population
might therefore lead to biased conclusions about pre-
dictor effects.
Predictors
The three studies investigated a wide variety of candidate
predictors, including clinical and laboratory predictors.
There was some overlap between models (see table 5),
with D-dimer, age and sex being the most commonly
included predictors. The Vienna model avoided the cat-
egorisation of continuous candidate predictors, while
the DASH model investigated patient age in prespeciﬁed
quartiles, to allow for non-linear associations between
age and recurrence risk. The HERDOO2 model in con-
trast performed χ2 testing to identify the optimal thresh-
old to dichotomise every continuous predictor under
consideration.
Data-driven analyses are known to incite reporting
biases, where optimal thresholds are reported without
any clinical meaning.47 Dichotomisation of continuous
predictors is also methodologically poor, as it seeks to
separate patients risk into two categories, treating all
those above the threshold as having the same constant
risk (and similarly for those below the threshold), which
is unrealistic in practice.47
All models also allowed for site of index event in some
way. Both the HERDOO2 and DASH models excluded
patients with distal DVT index events from their
studies,9 10 which is important risk stratiﬁcation in itself
(ie, both models are not applicable to patients with
distal DVT events). Only the Vienna model included
such patients and adjusted for site of index event as a
predictor in the model (see table 5). The Vienna
models predicted risks reﬂect the low risk of recurrence
associated with distal DVT index events, and provides an
estimate of risk (where the other models do not) which
may be a helpful tool in consultation with patients and
conﬁrm treatment decisions.14
Sample size
The HERDOO2 model was markedly underpowered,
having collected information on 69 predictors and con-
sidered at least 36 of these. There were only 91 recurrent
events (see table 2), meaning the HERDOO2 model
only had around 2.5 events per predictor (EPP), assum-
ing complete predictor availability for all patients.
Evidence shows that an EPP<10 can lead to bias in esti-
mates of predictor effects and their SEs, as well as the
coverage of CIs, with EPP=2 showing severe biases.48 49
This may then cause overﬁtted models (ie, models that
include inappropriate predictors or predictor effects
that are too large). The Vienna and DASH models inves-
tigated 15 and 14 candidate predictors, respectively, with
176 and 239 total events, respectively (see table 2).
Following the same rule of thumb (EPP<10)48 49 and
assuming complete predictor availability for all patients
(ie, no missing data), the Vienna ( just) and DASH
models therefore had sufﬁcient numbers of events to
assess the predictors of interest with appropriate statis-
tical power (see ﬁgure 2).
Missing data
All of the three included studies suffered from some
degree of missing predictor information, and used a
complete case analysis to overcome this issue. The pres-
ence of missing predictor data will further reduce the
apparent EPP discussed above (see ﬁgure 2). Each study
also used a selection procedure meaning more predic-
tors were considered, resulting in a higher proportion of
missing predictor data. For example, the Vienna predic-
tion model considered peak thrombin as a predictor, for
which 300 out of 929 patients had missing predictor
information.8 Similarly, the DASH model considered
predictors including BMI, for which only 802 out of
1818 patients had complete predictor information.10
Meaning that the predictor selection process included a
massively reduced sample size compared with the ﬁnal
model complete case data used, which may have
Table 5 Predictors included in final model
Model HERDOO2 Vienna DASH
Predictors included
D-dimer X X X
Age X – X
Sex – X X
BMI X – –
Post-thrombotic signs X – –
Site of index event – X –
Hormone therapy – – X
BMI, body mass index.
Table 4 Unprovoked venous thromboembolism definition
across studies
Model HERDOO2 Vienna DASH
Not provoked by
Trauma X X X
Surgery X X X
Cancer X X X
Pregnancy – X X
Immobility X – X
Hormone intake – X –
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increased the chance of spurious predictor–outcome
relationships (see ﬁgure 3).
No methods to assess the impact of this missing pre-
dictor information were used, and in the Vienna and
DASH models, the number of missing recurrent events
was not reported, so no assessment of the impact on stat-
istical power (nor EPP) could be made accurately. A
complete case analysis in the presence of missing data
does not represent the entire population, and reduces
sample size making predictor effects only pertinent to a
speciﬁc subgroup of the population with no missing
data. Multiple imputation (MI) can be used as a sensitiv-
ity analysis to assess the impact of missing data on the
performance of the model. MI using chained equations
imputes missing predictor information from a posterior
distribution based on the observed data50; it increases
sample size, power and may improve the generalisability
of the model.
Statistical analysis
A Cox proportional hazards model was used to develop
both the Vienna and DASH models, which appropriately
accounts for censoring of patients in the analysis of
time-to-event outcomes such as recurrence. The
HERDOO2 model used a conditional logistic model for
analyses, which does not account for the censoring of
patients over time and the variable lengths of individual
follow-up.
All studies recruited patients from different centres or
countries (see table 2); however, only one (DASH
model) stratiﬁed by source in their analyses.
Stratiﬁcation accounts for heterogeneity in the baseline
recurrence risk in different patient groups. Ignoring the
clustering of patients within centres or countries could
lead to poor model calibration (where model predic-
tions do not closely ﬁt observed recurrence rates) and/
or biased predictor effects,51 52 and thus could diminish
performance in a new setting. The DASH model did not
propose how to implement the model in practice; where
models are stratiﬁed, there are several options for imple-
mentation12 52 (eg, use a single intercept related to one
of the centres).
The HERDOO2 model excluded predictors from mul-
tivariable analysis where univariable analysis yielded
p≥0.2; this predictor selection strategy was therefore
completely data driven, which could lead to potential
bias in results, with predictor effects that may be import-
ant in combination being excluded. The DASH model
also excluded some predictors from multivariable ana-
lysis on the basis of univariable results. Univariable ana-
lyses are not recommended for decisions about
inclusion of predictors in a multivariable model.53
Both the Vienna and DASH models used bootstrapping
and shrinkage methods to adjust predictor coefﬁcients
for overoptimism, but the HERDOO2 development did
not account for optimism in predictor estimates. The use
of optimism correction methods reduces overﬁtting by
reducing the magnitude of predictor effects, to help
ensure the model performance is more accurate in a new
patient population.
The speciﬁcation and application of the proposed
models was described in various ways across the studies.
Both the Vienna and DASH models were presented well,
with an indication of how the predictors are combined to
calculate a patient’s recurrence risk at a speciﬁc time
point. Both provided cumulative recurrence risk at spe-
ciﬁc time points after cessation of therapy including an
estimate of the uncertainty surrounding these estimates
(95% CIs). This information could be used to direct the
decision-making process, informing clinicians and
patients of the individual’s level of risk, and therefore
allowing individualised treatment strategies. However,
neither reported any estimate or parameterisation of the
Figure 3 Final model sample size compared to total &
selection sample size. Final model sample size=total sample
minus patients with missing information in any predictor
included in the final model; Predictor selection sample
size=total sample size minus patients with missing predictor
information in any predictor considered for inclusion in the
model using a selection procedure.
Figure 2 Events per predictor (EPP) for included studies,
based on total sample size and number of predictors. NB:
lines represent number of events required to maintain EPP=x
for given number of predictors.
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baseline hazard function, which would be required for
full external validation of the model in a new setting.54–56
Conversely, the HERDOO2 model derived a clinical
decision rule splitting patients into those with less than
two predictors (from their model), and those with
greater than two predictors, suggesting that one group
should continue OAC therapy, while the other could
safely stop. The HERDOO2 model did not report indivi-
duals risk at speciﬁc time points, only that fewer than
two predictors would indicate a <3% annual risk of
recurrence. This therefore does not allow clinicians or
patients to make decisions based on their preference of
recurrence risk threshold, limiting the applicability
of the decision rule if a value other than 3% was of
interest.
Model validation
Model performance was evaluated using internal valid-
ation in all the studies, but none reported an external
validation.8–10 Internal validation was reported in terms
of calibration and discrimination with the Vienna and
DASH models presenting both (though not for the sim-
pliﬁed Vienna nomogram, which constitutes the ﬁnal
model). The HERDOO2 model presented neither cali-
bration nor discrimination statistics. The performance
statistics reported are given in table 6. Apparent
C-statistics (which represent the discriminatory perform-
ance within the development data without adjustment
for optimism using, eg, bootstrapping) are between 0.65
and 0.72 for the different models, indicating moderate
discrimination ability; however, apparent performance is
likely to be optimistic. The Vienna model also presented
a bootstrap adjusted C-statistic (accounting for opti-
mism), of 0.646 for predictions at 5 years postcessation
of therapy, indicating a small reduction after accounting
for optimism. The Vienna and DASH models also pro-
vided a bootstrap optimism-adjusted calibration slope
(or uniform shrinkage factor), which showed moderate
calibration performance of 0.88 for the Vienna model,
and strong performance of 0.97 for the DASH model
(with 1 indicating perfect calibration). Both the Vienna
and DASH models used their shrinkage factor to adjust
the predictor effect values in their ﬁnal model, to adjust
for the overoptimism.
External validation is the true indication of model per-
formance in the wider population, as a model validated
within its development data set will give optimistic per-
formance statistics.11 54 57 External validation studies are
currently being undertaken to validate both the
HERDOO2 model28–30 and the Vienna model,27 which
will provide a more robust indication as to the overall
performance (in terms of calibration and discrimin-
ation) of these models in new patient populations where
they are intended for use. The REVERSE II study is a
randomised trial aiming to compare the use of the
HERDOO2 model to decide on cessation of OAC
therapy, compared with standard practice.28 30 The
VISTA study is a randomised trial comparing the use of
the Vienna model to decide on treatment duration, with
usual care where treatment duration is based on physi-
cians judgement.27
Update to the Vienna prediction model
The authors of the Vienna model also recently devel-
oped an update to the original Vienna model, with the
aim of predicting recurrence risk at later time points
using updated D-dimer measurements.44 New D-dimer
measurements were taken at 3, 9 and 15 months postces-
sation of therapy, with analyses showing a slight decrease
in HRs for the effect of log D-dimer over time (though
the 95% CIs remained similar).44 Three new nomo-
grams were developed for use in practice to predict
recurrence risk at 12 and 60 months from time of new
D-dimer measurement. A web-based calculator was also
developed by the authors allowing prediction of recur-
rence risk at any integer month after baseline (3 weeks)
and up to 15 months postcessation of therapy.
The updated model was adjusted for optimism using
leave-one-out resampling to calculate shrinkage factors for
3, 9 and 15 months of 0.79, 0.81 and 0.7, indicating moder-
ate calibration of the model but reduced performance
compared with the original Vienna model (optimism-
adjusted calibration slope=0.88). Discriminatory perform-
ance for 5-year predictions at each new time point showed
Table 6 Internal validation performance statistics
Model Calibration slope* Apparent discrimination† Bootstrap-adjusted discrimination‡
HERDOO2
Model for use (score) – – –
Development model (β terms) – – –
Vienna
Model for use (nomogram) – – –
Development model (β terms) 0.88 0.651 60 months=0.646
DASH
Model for use (score) – 0.71 –
Development model (β terms) 0.974 0.72 –
*Bootstrap calibration slope.
†C-statistic based on development data.
‡C-statistic based on bootstrap internal validation.
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a small reduction in performance compared with the ori-
ginal model (optimism-adjusted area under the curve
(AUC) values were 0.61, 0.61 and 0.58, for 3, 9 and
15 months, compared with AUC=0.646 for the original
model).8 44 The updated Vienna model expands the
earlier model by allowing dynamic prediction of recur-
rence risk over time, but while the earlier Vienna model
has recently been externally validated,18 this model has not
been externally validated to date, and shows inferior
internal validation performance statistics compared with
the original model.
Relevant articles identified outside of review search dates
Subsequent to the completion of our review searches,
two additional highly relevant studies were identiﬁed.18 19
The ﬁrst was an external validation of the Vienna predic-
tion model using IPD from ﬁve studies, which aimed to
assess the performance of the Vienna model in terms of
discrimination and calibration in a new population.18 20
The study reported that the derivation and validation
populations were homogeneous after removal of patients
with provoked VTE and those with missing predictor
information.18 Discrimination was calculated using the
C-statistic for comparison to the original Vienna model,
with a C-statistic in the validation cohort of 0.626 com-
pared with 0.646 (the optimism-adjusted discrimination
—see table 6) for the derivation data, indicating a reduc-
tion in the discriminatory performance of the model in
a new setting.
The true calibration of the model in the validation
data could not be assessed without the baseline hazard
function.54–56 58 As the original Vienna model was devel-
oped using a Cox model which does not parameterise
the baseline hazard function, this meant that assump-
tions about the shape of the baseline hazard function
had to be made.18 54–56 The authors recalibrated the
Vienna model assuming a Weibull distribution; however,
because this new component of the model was devel-
oped, this new model would itself require further exter-
nal validation.54–56 As the authors could not use the Cox
model directly to predict survival probabilities (due to
the lack of baseline hazard function), they could only
assess weak calibration using the prognostic index to
make predictions within the validation data.54 58
Comparison of observed and expected survival probabil-
ities in ﬁve risk groups showed a general trend for the
Vienna model to underpredict the risk of VTE recur-
rence at 12 months postcessation of therapy.18 It should
be noted that the study did not validate the simpliﬁed
Vienna nomogram proposed for use in practice.18 54
The second study identiﬁed was an external validation
of the updated Vienna model in a prospective multicen-
tre cohort study.19 The study aimed to validate the
updated model in elderly patients over 65 years old, and
assessed the model’s performance in terms of discrimin-
ation and the proportion of recurrent events between
high-risk and low-risk patients deﬁned by the model.
The study found no difference between the proportion
of recurrences in the low-risk versus high-risk groups
(where recurrence risk <6.2% 12 months was deﬁned as
low risk). Discriminative performance was poor at both
12 and 24 months, with C-statistics of 0.39 (95% CI 0.25
to 0.52) and 0.43 (95% CI 0.31 to 0.54), respectively.
The study suffered from a very low number of events,
17 and 26 by 12 and 24 months, respectively. Therefore,
the conclusions of the study should be interpreted with
caution, as it is known that small validation samples tend
to show poor calibration and discrimination perform-
ance, with current recommendations indicating that val-
idation sample sizes should be a minimum of 100 events
and preferably ≥200 events.58 59 Also there were several
distinct differences between the derivation patient popu-
lation for the updated Vienna model and the validation
sample used by Tritschler and colleagues which naturally
led to heterogeneity in model performance. In particu-
lar, the validation study used a much older population
(median (IQR) age 74 (69–79.8) vs 54 (43–63) in the
derivation population). This also led to differences in
D-dimer levels, with the elderly patients in the validation
study having much higher D-dimer levels (median
(IQR) D-dimer 1022 (607–1755) vs 355 (236–558) in
the derivation population). Further to this, women in
the validation study appeared to have much greater risk
of recurrence than men, which is discordant with
current evidence suggesting that men are between 1.5
and 2 times more likely to suffer a recurrence.8–10 60 61
These differences in baseline characteristics may mean
that the predictor effects in the updated Vienna model
are miscalibrated when applied in this new population,
leading to the poor performance seen in the validation
study.
Quality assessment and risk of bias summary of
HERDOO2, Vienna and DASH models
Quality assessment based on an early version of the
PROBAST tool showed that there was evidence through-
out the included studies of a moderate-to-high risk of
bias (see table 7), predominately because of a lack of
external validation (see tables 6 and 7). The HERDOO2
model development suffered high risk of bias, and some
marked methodological issues, including the choice of
analysis model, substantially underpowered analyses,
data-driven categorisation of predictors, lack of adjust-
ment for optimism and poor presentation of the model
for use (see table 7). In contrast, the Vienna prediction
model and DASH score were considered generally meth-
odologically sound in terms of their development. Both
had statistical power to investigate their candidate pre-
dictors, accounted for optimism in their selection proce-
dures, and the Vienna study assessed continuous
predictors without categorisation and loss of information
(though the DASH study did categorise continuous pre-
dictors). Both studies presented their proposed models
more clearly than the HERDOO2 model, indicating the
recurrence rate associated with predictor values and the
uncertainty around those estimates. However,
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predictions were only provided for particular, discretised
values of risk, for example, both models provide predic-
tions for only a small selection of time points (Vienna
model for 12 and 60 months post-therapy, DASH score
for 1, 2 and 5 years from cessation of therapy); both
models only provide 95% CIs for a small selection of
predicted annual recurrence rates.
Despite being of generally good methodological
quality for development, both Vienna and DASH were
classed at moderate risk of bias due to a lack of sufﬁcient
external validation (see table 7). The DASH score has
received no external validation, and any such future val-
idation should account for the method of implementa-
tion, which was not proposed by the authors. The
Vienna model has now been externally validated (as dis-
cussed above), but issues remain because: (1) validation
performance was shown to be lower than expected and
uncertainty was high;18 (2) a new Weibull model
component was added, which itself requires additional
validation;54–56 (3) the nomogram version of the model,
which is the most used, was not validated54 and (4) valid-
ation of the updated dynamic Vienna prediction model
in a new population also indicated poor performance.
Thus, until further external validation is undertaken and
the results of ongoing validation trials are available, the
true performance in new populations cannot be
ascertained.
DISCUSSION
This systematic review of prognostic models for VTE
recurrence risk identiﬁed four full-text articles develop-
ing three independent prognostic models.8–10 44 A cri-
tique of the included studies described and identiﬁed
the strengths and weaknesses of the studies with a
particular focus on methods of patient selection,
outcome reporting, predictor selection, sample size,
model development and validation.
First, a key ﬁnding was the different deﬁnitions of unpro-
voked VTE across the included studies (see table 4). The
Vienna model study excluded patients with index events
provoked by use of female hormones, such as the contra-
ceptive pill or hormone replacement therapy, while the
HERDOO2 and DASH studies deﬁned index events
related to hormone use as unprovoked. Risk factors con-
sistently deﬁned as provoking across the studies included
surgery, trauma, immobility and pregnancy (see table 4).
The use of varying deﬁnitions to describe the unpro-
voked population creates confusion as to which popula-
tion the proposed models are applicable to. Further
research in developing prognostic models to predict
recurrence risk in an unprovoked population should aim
to use a standard, consistent deﬁnition for the popula-
tion, excluding patients with acquired/removable risk
factors,4 to ensure that model predictions are reliable for
intended patients. Given the deﬁnition of unprovoked
VTE used in the DASH and HERDOO2 studies, the pro-
posed models may not be applicable within an unpro-
voked population.3 4
Across the included studies, various predictors were
included within the proposed ﬁnal models, with sex, site
of index event and D-dimer level (post-therapy) being
included consistently within all three models, indicating
strong evidence of an association with recurrence risk
(see table 5). As such any future model development
should consider including these predictors, as they
appear prognostic for recurrence risk, and thus evaluate
new predictors in addition to these. Indeed the discrim-
ination performance shown in current models was mod-
erate at best, and therefore any new model would ideally
Table 7 Quality considerations for included studies
Model HERDOO2 Vienna DASH
Use of a selection procedure? Yes Yes Yes
Adjustment for optimism in selection procedure? No Yes Yes
Events per predictor >10? No Yes Yes
Appropriate type of model? No Yes Yes
Modelled continuous predictors as linear/non-linear? No Yes No
Considered multiple imputation to handle missing
data?
No No No
Adjustment for optimism in internal validation? Yes Yes Yes
Reported discrimination? No Yes* Yes
Reported calibration? No Yes* Yes*
Were final model predictor weightings related to
regression coefficients?
Yes Yes Yes
Internal validation? No Yes* Yes
External validation? No Yes* No
Risk of bias? High Moderate Moderate
Key reason for decision No external validation/several
quality issues
External
validation
No external
validation
*Not for the nomogram/score used in practice.
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include additional predictors to improve the discrimin-
atory performance statistically, though a parsimonious
model may better facilitate implementation in prac-
tice.14 62 While it has been discussed that the effect of
D-dimer as a predictor may be dependent on the
method/assay used, previous research has investigated
the link between variability in D-dimer assays and recur-
rent VTE, and found that varying assays do not alter the
prognostic value of D-dimer in predicting recurrence.20
After evaluation of the models’ development and val-
idation criteria, all models were labelled with at least a
moderate risk of bias. This was mainly due to a lack of
robust external validation, which is essential as prognos-
tic model performance is known to be optimistic when
evaluated on the same data used to develop the
model.11 The HERDOO2 model development was
classed at high risk of bias, as—alongside no external
validation—it had methodological concerns, including
the choice of analysis model, substantially underpow-
ered analyses, data-driven categorisation of predictors,
lack of adjustment for optimism and the presentation
of the model for use.9 The Vienna model and DASH
score were methodologically sound, as they had
adequate statistical power to investigate their candidate
predictors, accounted for optimism in their selection
procedures, the Vienna model assessed continuous pre-
dictors without categorisation and loss of information,
and both presented their proposed models clearly.8 10
However, until further external validation is performed,
the true performance in new populations cannot be
ascertained.
The new external validation study for the Vienna
model adds important information on the applicability
of the model in practice. The study shows that the ability
of the model to identify those at high and low risk of
recurrence is weaker in a new population outside of the
derivation data set.18 However, it is important for the
Vienna model to undergo further validation, because
the validation study related to the ﬁtted model (ie, the
prognostic index from the ﬁtted Cox model), and not
the nomogram (which potentially used a simpliﬁed set
of regression coefﬁcients) which was recommended for
use. The updated dynamic Vienna prediction model has
now also been externally validated in an elderly popula-
tion, which showed poor discriminatory performance,
but suffered from small validation sample sizes and large
variations in case-mix from the original model’s
intended population.19
To our knowledge, this is the ﬁrst systematic review
identifying prognostic models for VTE recurrence risk
in the unprovoked population, and as such it is a
strength of the study that a robust systematic method-
ology was used, which yielded a large amount of poten-
tial research, making it unlikely that any relevant study
was not included. However, a limitation of the review is
that at this time, the searches performed are somewhat
out of date, though efforts have been made to include
relevant articles identiﬁed since the search end dates.
A limitation of this review is that the conclusions and
quality classiﬁcations for the prognostic models dis-
cussed in this article are based on the reporting stan-
dards of the original articles. Further, we were unable
to perform a quantitative analysis of the identiﬁed arti-
cles due to a lack of homogeneity in many areas,
including the predictors used, model types and study
populations.
In conclusion, currently available models to predict
risk of recurrent VTE in an unprovoked population have
several limitations. In particular, sufﬁcient external valid-
ation has not yet been performed for two of the avail-
able models and we recommend further validation
studies are required before the models are implemented
into practice. Even then the impact of the model on
clinical decision-making and, crucially, patient outcomes
should be evaluated through a randomised trial, ideally,
or health economic modelling exercise.11 43 Any new
models should try to build on the existing work, ensure
external validation in multiple populations, transparency
in reporting of model development as outlined in the
TRIPOD statement,13 and ﬁnally improved statistical
analyses to ensure model predictions are more robust.
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